FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/10/075441 [Registered on: 17/10/2024] Trial Registered Prospectively
Last Modified On: 11/10/2024
Post Graduate Thesis  No 
Type of Trial  Observational 
Type of Study   Cross Sectional Study 
Study Design  Other 
Public Title of Study   Clinical findings, hormonal tests, genetic tests and quality of life assessment in patients with abnormal male genitalia 
Scientific Title of Study   Clinical profile, hormonal profile, genetic profile and quality of life assessment in patients with 46XY karyotype with Disorders of sex development 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Nikhil Bhagwat 
Designation  Professor 
Affiliation  Topiwala National Medical College & Bai Yamunabai Laxman Nair Charitable Hospital, Mumbai 
Address  Department of Endocrinology Room 419 4th floor College building Topiwala National Medical College BYL Nair Ch Hospital RTO Colony Mumbai Central Mumbai Maharashtra 400008

Mumbai
MAHARASHTRA
400008
India 
Phone  9820238399  
Fax    
Email  bhagwatnik@yahoo.co.in  
 
Details of Contact Person
Scientific Query
 
Name  Dr Abraham Alex Kodiatte 
Designation  Senior Resident 
Affiliation  Topiwala National Medical College & Bai Yamunabai Laxman Nair Charitable Hospital, Mumbai 
Address  Department of Endocrinology Room 419 4th floor College building Topiwala National Medical College BYL Nair Ch Hospital RTO Colony Mumbai Central Mumbai Maharashtra 400008

Mumbai
MAHARASHTRA
400008
India 
Phone  9780280094  
Fax    
Email  abrahamkodiatte@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Abraham Alex Kodiatte 
Designation  Senior Resident 
Affiliation  Topiwala National Medical College & Bai Yamunabai Laxman Nair Charitable Hospital, Mumbai 
Address  Department of Endocrinology Room 419 4th floor College building Topiwala National Medical College BYL Nair Ch Hospital RTO Colony Mumbai Central Mumbai Maharashtra 400008

Mumbai
MAHARASHTRA
400008
India 
Phone  9780280094  
Fax    
Email  abrahamkodiatte@gmail.com  
 
Source of Monetary or Material Support  
Dept of Endocrinology, T.N. Medical College & BYL Nair Charitable Hospital, Mumbai 
 
Primary Sponsor  
Name  Dept of Endocrinology, T.N. Medical College & BYL Nair Charitable Hospital, Mumbai 
Address  Department of Endocrinology, Room 419, 4th floor, College building, Topiwala National Medical College & Bai Yamunabai Laxman Nair Charitable Hospital, RTO Colony, Mumbai central, Mumbai, Maharashtra - 400008 
Type of Sponsor  Government medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Abraham Alex Kodiatte  Dept of Endocrinology, T.N. Medical College & BYL Nair Charitable Hospital, Mumbai  Department of Endocrinology, Room 419, 4th floor, College building Topiwala National Medical College & Bai Yamunabai Laxman Nair Charitable Hospital, RTO Colony, Mumbai central, Mumbai, Maharashtra - 400008
Mumbai
MAHARASHTRA 
9780280094

abrahamkodiatte@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Ethics Committee for Academic Research Projects (ECARP), PG Academic Committee, T.N. Medical College & BYL Nair Ch. Hospital  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: Q562||Female pseudohermaphroditism, notelsewhere classified, (2) ICD-10 Condition: Q560||Hermaphroditism, not elsewhere classified, (3) ICD-10 Condition: Q541||Hypospadias, penile, (4) ICD-10 Condition: Q542||Hypospadias, penoscrotal, (5) ICD-10 Condition: Q543||Hypospadias, perineal, (6) ICD-10 Condition: Q564||Indeterminate sex, unspecified, (7) ICD-10 Condition: Q561||Male pseudohermaphroditism, not elsewhere classified, (8) ICD-10 Condition: Q563||Pseudohermaphroditism, unspecified, (9) ICD-10 Condition: Q532||Undescended testicle, bilateral,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  NIL  no Intervention is given to the patients 
 
Inclusion Criteria  
Age From  0.00 Year(s)
Age To  99.00 Year(s)
Gender  Both 
Details  1. Overt genital ambiguity
2. Apparent female genitalia with an enlarged clitoris, posterior labial fusion, or an inguinal/labial mass
3. Apparent male genitalia with bilateral undescended testes, micropenis, isolated perineal hypospadias, or mild hypospadias with undescended testis
4. Discordance between genital appearance and a prenatal karyotype
5. External Masculinisation Score of less than 11
6. All patients with 46XY karyotype diagnosed to have disorders of sex development who provide consent to be part of the study 
 
ExclusionCriteria 
Details  1. Subjects diagnosed to have differences/ disorders of sex development who do not have a 46XY karyotype

2. Patients who do not consent to be part of study 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
To compare the clinical phenotype, hormonal profile and genetic profile among patients with various subtypes of 46XY DSD  At the time of presentation in the outpatient dept of the hospital 
 
Secondary Outcome  
Outcome  TimePoints 
To assess and compare patients within the various subtypes of 46XY DSD, the Gender identity/ Gender Role Behaviour/ Gender Dysphoria using questionnaires  At the time of presentation in the outpatient dept of the hospital 
To assess and compare patients within the various subtypes of 46XY DSD, the Patient’s Quality of life using questionnaires  At the time of presentation in the outpatient dept of the hospital 
To assess and compare patients within the various subtypes of 46XY DSD, the Patient’s sexual functions  At the time of presentation in the outpatient dept of the hospital 
To assess and compare patients within the various subtypes of 46XY DSD, the Parent’s Quality of life using questionnaires  At the time of presentation in the outpatient dept of the hospital 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   22/10/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - YES
  1. What data in particular will be shared?
    Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).

  2. What additional supporting information will be shared?
    Response -  Study Protocol
    Response - Clinical Study Report

  3. Who will be able to view these files?
    Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.

  4. For what types of analyses will this data be available?
    Response - For individual participant data meta-analysis.

  5. By what mechanism will data be made available?
    Response - Proposals should be directed to [abrahamkodiatte@gmail.com].

  6. For how long will this data be available start date provided 01-06-2025 and end date provided 02-06-2028?
    Response - Beginning 9 months and ending 36 months following article publication.

  7. Any URL or additional information regarding plan/policy for sharing IPD? 
    Additional Information - NIL
Brief Summary  

Research Hypothesis: Concordance of clinical, biochemical and genetic diagnosis is variable among various subtypes of 46XY Disorder of sex development (DSD)

 Research Question: 1. Does genetic diagnosis differ from overall clinical and/or biochemical diagnosis?

2. Do psychosocial outcomes, gender identity and quality of life differ in various subtypes of 46XY DSD?

3. What is the quality of life in parents of patients affected with 46XY DSD and is it poorer?

Summary:

Differences/ Disorders of sex development (DSD) encompass a group of congenital conditions in which there exists a discrepancy in the chromosomal sex, gonadal sex or phenotypic/ anatomic sex; resulting in atypical presentation of the same. It is to be noted that none of these processes absolutely define a person’s sex or gender identity. 


Etiology

DSD can arise due to:

1.     Differences in number and structure of sex chromosome

2.     Variations in genes responsible for genitalia and gonadal development

3.     Disorders related to steroidogenesis pathway of adrenals and gonads

4.     Maternal factors (Exogenous and endogenous)

5.     Endocrine disruptors, altering gentalia development

 

Genetics

Historically, clinical phenotype, in correlation with hormonal tests, anatomical imaging have guided single gene-based testing (Sanger sequencing). This approach had a poor yield, owing to reasons that phenotype-genotype correlation was poor and phenotypes do overlap, which is why, with advances in genomics, the approach was shifted to a multi-gene testing.

 

Exome sequences and panel-based testing is currently available for diagnostic evaluation. Exome sequencing has an advantage of identifying known genes, as well as facilitates discovery of novel genes. Even in those who have a negative gene screening, since data regarding the genomics  is constantly evolving, there is data and studies to suggest that reanalysis of data after a certain period of 2-3 years, can increase diagnostic yield to by ~10%.

Phenotype-hormonal profile-genotype correlation

Each of these entities present in  a similar fashion, with degree of masculinisation variable in each of these cases. Hormonal evaluation may help narrow down the diagnosis, with certain ratios being introduced to help guide diagnostic evaluation.

The heterogeneity in presentation of patients with DSD owes to the complex mechanisms governing the development of reproduction systems.  Similarly, there are a number of genes responsible for the DSD pathogenicity. The wide spectrum of phenotypic presentation and a plethora of genes associated with the same clinical phenotype makes it vital to pinpoint the gene involved, with the help of diagnostic algorithms and advancement in genomics. Here came the Next-Generation Sequencing technology, which improved the diagnostic yield.

Need for genetic diagnosis

Reaching the genetic diagnosis is important due to the reasons enumerated below(4–7)

1.     Provides add-on details to management algorithm

2.     Gonad germ-line tumour risk

3.     Achieving long-term optimal outcomes

4.     Contributes to solution to gender identity uncertainty

5.     Genetic counselling to parents and potential risk to consequential fetus recurrence

6.     Predict prognosis

7.     Predicts the risks in family members

8.     Information on associated anomalies/ comorbidities, including adrenal health

9.     Mutation positive 46XY DSD patients have a more varied phenotype compared to mutation negative, which will require a tailored approach to management.

10.  Guide on deciding sex of rearing

11.  Guides timing of genitoplasty surgery or medical therapy

12.  Certain DSD  subtypes do not have a pathognomonic hormonal signature

13.  Detection of other associated organ involvement may be of importance inorder to diagnosis, screening and prevention.

14.  Need for additional behavioural and educational support in patients with sex chromosome DSD

15.  Guidance on long-term fertility and need for fertility preservation options

16.  Counselling couples contemplating future pregnancy

17.  Counselling patients about the likely course of their condition

18.  Contributes to clinical knowledge

19.  Provides reassurance to patients and their families


Psychosocial Impact

Psychosexual development plays an important role in the formation of sexual identity and is the main component of sexual identity, which is influenced by genetic status, pre/postnatal exposure to androgens, sociocultural factors, and family dynamics. Gender assignment is an important problem in DSD patients who have a virilized brain with undervirilised external genitalia.

DSD can impose a high degree of stress on patients and their families and exert a wide range of effects on ‘social and psychosexual adjustment, mental health, quality of life and social participation’. Common problems with 46XY patients with DSD are: psychosocial concerns, with issues involving gender identity, gender dysphoria, social stigmatisation, infertility, body dissatisfaction with their body and sex life , lower self-esteem; resulting in a poorer quality of life. It appears that having a DSD can be accompanied by a wide range of psychologically relevant concerns.

Long-term psychological, physical, and social outcomes in those with DSD are unclear and lack literature. clinical parameters, mutation analysis and surgical outcomes have been studied upon; health-related quality of life assessment are an important  tool to evaluate outcomes, especially in patients with DSD, since it takes into account multiple dimensions. Psychosexual determinants including gender identity/gender dysphoria and gender role behaviour are all very unique issues pertinent to DSD. Each DSD subtype has its own psychosexual signature, which each individual may or my not conform to. Patients with Complete androgen insensitivity syndrome (subtype of DSD) are almost always raised as females (female gender identity), with a small number of them developing gender dysphoria. Patients with Partial androgen insensitivity syndrome on the other hand, are more likely to identify with a gender that is incongruent with their sex of rearing. Similarly, other subtypes of DSD have their own hormonal signatures, influenced by social and behavioural factors, which may or may not lead to a gender dysphoria.

Hence there is a need to screen and assess for quality of life parameters 


 
Close